A new method of monitoring
breast cancer risks has been developed by NeoMatrix which is based in Irvine,
California. NeoMatrix develops innovative devices that allow women and their
doctors to promote optimal breast health. The
Halo Breast Pap Test
is the only fully automated, noninvasive breast disease
screening device.
All women are at risk for
developing
breast cancer, and in the United States along we spend over $3
billion annually on breast cancer screening. Although 70% of all lumps found
are discovered during self exams. The unfortunate issue is that by the time
breast cancer can be felt, it is no longer in its earliest or most treatable
stage.
This new method of breast
cancer screening allows patients to fight breast cancer before you will even
have it. Halo is a five minute non-invasive test that can help determine your
risk of breast cancer years earlier than a traditional mammogram.
Halo Breast Pap Test
is supposed to be used as a conjunctive method along side of a mammogram or self
breast exam. This non-invasive test can detect abnormalities at the cellular
level years earlier before mammograms can detect a lump. This test is
recommended for women from ages of 25 – 55 years.
Cells from Nipple Aspirate Fluid (NAF)
can provide clues to a woman's breast health; routine screening will alert a
woman and her doctor to changes in her cytology
A finding of atypia, years before it might develop into a lesion, will allow
a woman and her doctor the opportunity to chart the optimal care path